Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
raltegravir + atazanavir
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Raltegravir + atazanavir is a combination antiretroviral therapy used for HIV-1 infection treatment. This regimen combines two different antiretroviral drug classes: raltegravir (an integrase strand transfer inhibitor) and atazanavir (a protease inhibitor). This combination is particularly attractive as a "nuke-sparing" option that excludes nucleoside reverse transcriptase inhibitors (NRTIs) and ritonavir, potentially reducing metabolic toxicity. Raltegravir inhibits HIV integrase, preventing viral DNA integration into the host cell genome, while atazanavir selectively inhibits HIV-1 protease, preventing the formation of mature virions. Studies have shown this combination maintains virologic control in treatment-experienced patients and may improve metabolic parameters, particularly lipid profiles, when used as a switch strategy from other regimens[1][5].
- Brand names
- ReyatazIsentress
- Other names
- RAL/ATZ
02
Targets
Integrase allosteric pocket (HIV)PR (Progesterone receptor)
Beyond the preview
Go deeper on raltegravir + atazanavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on raltegravir + atazanavir.